Lantern Pharma Advances ADC Program Across Multiple Solid Tumor Cancers

Author: Benzinga Newsdesk | February 15, 2024 09:07am

• Lantern, in collaboration with academic research partners, has advanced the development, synthesis, and preclinical proof-of-concept of a novel, highly potent, cryptophycin-based ADC.
• The cryptophycin ADC has shown picomolar potency in a wide range of solid tumors tested in preclinical development and is being further evaluated for clinical potential in six solid tumor indications.
• The company has leveraged RADR®, a proprietary AI platform for oncology drug development, for target selection and molecular payload characterization in ADCs, and a unique, controlled conjugation approach for maximizing drug-to-antibody ratios while controlling for non-specific conjugation.
• Lantern expects to move towards IND development of the ADC program during 2024 with a focus on select solid tumors that are unresponsive or refractory to current therapies.
• ADCs are a promising and emerging class of cancer therapy that are expected to generate over $24 billion in revenue by 2030 and have been the focus of several recent M&A transactions among emerging biotech companies and global pharmaceutical companies.

Posted In: LTRN